Drug Profile
Research programme: dendrimer-based proteins and monoclonal antibodies - Starpharma
Alternative Names: ADME Engineering; Dendrimer-antibodies; Dendrimer-monoclonal antibody formulations - Starpharma; Dendrimer-protein formulations - Starpharma; Dendrimer-proteinsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Starpharma
- Class Dendrimers; Monoclonal antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Australia (Parenteral)
- 19 Dec 2011 Starpharma and Eli Lilly and Company expand their development collaboration; preclinical development is ongoing
- 29 Feb 2008 Early research in Undefined indication in Australia (Parenteral)